Emtricitabine + Tenofovir Alafenamide

This medicine pairs emtricitabine, a nucleoside reverse-transcriptase inhibitor (NRTI), with tenofovir alafenamide, a nucleotide reverse-transcriptase inhibitor that is a prodrug of tenofovir. Both belong to the backbone class of HIV drugs that interfere with reverse transcriptase. The combination is marketed as Descovy and also serves as the two-drug backbone of several complete single-tablet HIV regimens ^[2].

Tenofovir alafenamide is a newer prodrug of tenofovir designed to carry the active drug into cells at much lower blood concentrations than the older prodrug, tenofovir disoproxil fumarate (TDF). Because circulating tenofovir levels are far lower, tenofovir alafenamide produces smaller reductions in kidney function and bone mineral density. Phase 3 trials in previously untreated people with HIV showed that a tenofovir alafenamide-based regimen suppressed the virus as well as a TDF-based one while causing significantly less kidney and bone effect ^[2].

The emtricitabine and tenofovir alafenamide combination is used both to treat established HIV infection, as part of combination therapy, and to prevent HIV in people at risk, a strategy called pre-exposure prophylaxis (PrEP). In the DISCOVER trial, emtricitabine and tenofovir alafenamide was as effective as the older emtricitabine and TDF combination for PrEP ^[1]. For prevention it was approved only for certain routes of exposure, because it was not studied in people at risk through receptive vaginal sex ^[1][3].

The combination is generally well tolerated, and its main advantage over the TDF-based product is a more favorable bone and kidney safety profile, which can guide the choice between the two for an individual patient; a possible trade-off is a tendency toward modest weight gain and higher blood lipids with tenofovir alafenamide ^[3]. It is taken as a single once-daily tablet and is available on its own and within combined HIV regimens. Anyone considered for it as prevention must first be confirmed to be HIV-negative.

This combination is prescription only and generally well tolerated. Common effects include nausea, headache, fatigue and diarrhea, and the tenofovir alafenamide form is associated with modest weight gain and small rises in cholesterol. Both drugs are active against hepatitis B, so stopping them abruptly in a coinfected person can trigger a severe liver flare. For PrEP, HIV-negative status must be confirmed before starting and tested regularly, since taking it with undiagnosed HIV can breed resistance. DISCOVER supported PrEP use in men and transgender women, but it was not studied for people at risk from receptive vaginal sex.

This fixed-dose combination pairs two reverse-transcriptase inhibitors, emtricitabine and tenofovir alafenamide, and was developed by Gilead Sciences, which markets it as Descovy. Its central advance is tenofovir alafenamide, a second-generation prodrug of tenofovir engineered to remain stable in the bloodstream and convert to its active form mainly inside cells; this achieves effective intracellular drug levels at far lower plasma concentrations than the older tenofovir disoproxil fumarate, which in turn spares the kidneys and bones.

The combination was first approved in 2016 as a backbone for HIV treatment regimens. In October 2019 the United States Food and Drug Administration approved it for HIV pre-exposure prophylaxis (PrEP) in at-risk adults and adolescents, excluding those at risk through receptive vaginal sex, a decision grounded in the large DISCOVER trial reported by Mayer and colleagues in The Lancet in 2020, which found it non-inferior to the established emtricitabine-tenofovir disoproxil fumarate regimen for HIV prevention.

Emtricitabine with tenofovir alafenamide is well regarded as a modern, kidney- and bone-sparing option for both treating and preventing HIV, delivered as a single once-daily tablet. In the DISCOVER trial it matched the long-established PrEP standard for effectiveness while showing more favorable markers of renal function and bone density, which is meaningful for people who will take the medication for many years. As part of PrEP it offers highly effective protection against acquiring HIV when taken consistently.

A fair account notes the boundaries of its approval: unlike the older combination it has not been shown effective for prevention in people at risk through receptive vaginal sex, so it is not indicated in that group, and like all PrEP it requires HIV-negative status confirmation, ongoing testing, and good adherence to work. Within those parameters it is a highly effective and well-tolerated tool in HIV prevention and treatment.